The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Relative effectiveness of letrozole alone or in sequence with tamoxifen for patients diagnosed with invasive lobular carcinoma.
Otto Metzger Filho
No relevant relationships to disclose
Anita Giobbie-Hurder
No relevant relationships to disclose
Elizabeth A Mallon
No relevant relationships to disclose
Giuseppe Viale
No relevant relationships to disclose
Eric P. Winer
No relevant relationships to disclose
Beat J. K. Thurlimann
Stock Ownership - Novartis
Richard D. Gelber
No relevant relationships to disclose
Meredith M. Regan
No relevant relationships to disclose
Marco Colleoni
Research Funding - Novartis
Bent Ejlertsen
Research Funding - Novartis
Herve Bonnefoi
No relevant relationships to disclose
John F. Forbes
Honoraria - AstraZeneca; Novartis
Research Funding - Novartis
Patrick Neven
No relevant relationships to disclose
Andrew M. Wardley
Honoraria - Novartis
Research Funding - Novartis
Istvan Lang
No relevant relationships to disclose
Ian E. Smith
No relevant relationships to disclose
Karen N. Price
No relevant relationships to disclose
Alan S. Coates
No relevant relationships to disclose
Aron Goldhirsch
No relevant relationships to disclose